North China Pharmaceutical Company.Ltd (SHA:600812)

China flag China · Delayed Price · Currency is CNY
5.25
+0.03 (0.57%)
Apr 28, 2026, 3:00 PM CST
Market Cap9.01B -14.8%
Revenue (ttm)8.82B -6.4%
Net Income161.04M +44.1%
EPS0.09 +44.6%
Shares Out1.72B
PE Ratio55.76
Forward PEn/a
Dividend0.04 (0.67%)
Ex-Dividend Daten/a
Volume9,423,286
Average Volume24,769,881
Open5.22
Previous Close5.22
Day's Range5.21 - 5.27
52-Week Range5.01 - 7.46
Beta0.43
RSI39.57
Earnings DateApr 18, 2026

About SHA:600812

North China Pharmaceutical Company.Ltd engages in the research and development, production, and sales of pharmaceutical products in China and internationally. The company primarily offers anti-infective drugs, biotechnology drugs, cardiovascular cerebrovascular, immunomodulators, and vitamins and health products. It also provides chemical pharmaceuticals; and biological, agricultural, and veterinary drugs. North China Pharmaceutical Company.Ltd was founded in 1992 and is headquartered in Shijiazhuang, China. [Read more]

Sector Healthcare
Founded 1992
Employees 10,000
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600812
Full Company Profile

Financial Performance

In 2025, SHA:600812's revenue was 9.24 billion, a decrease of -6.36% compared to the previous year's 9.87 billion. Earnings were 183.06 million, an increase of 44.15%.

Financial Statements